Pigmented Villonodular Synovitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Pigmented Villonodular Synovitis (PVNS) is a condition that causes synovium. PVNS is characterized by inflammation and overgrowth of the joint lining. This affects the hip or knee. Symptoms include pain, swelling in the affected joint, locking, catching, and instability in the joint. Treatment includes surgery and radiation therapy.
The PVNS pipeline drugs market research report provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for PVNS and features dormant and discontinued projects.
PVNS Pipeline Drugs Market Segmentation by Targets
Some of the targets of the PVNS pipeline drugs market are Macrophage Colony Stimulating Factor 1 Receptor, Bcr-Abl Tyrosine Kinase, Peroxisome Proliferator Activated Receptor Gamma, Programmed Cell Death 1 Ligand 1, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, and Toll Like Receptor 9.
PVNS Pipeline Drugs Market Analysis, by Targets
For more PVNS pipeline drugs market target insights, download a free report sample
PVNS Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Pigmented Villonodular Synovitis pipeline drugs market are Macrophage Colony Stimulating Factor 1 Receptor Antagonist, Bcr-Abl Tyrosine Kinase Inhibitor, Peroxisome Proliferator Activated Receptor Gamma Agonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, and Toll Like Receptor 9 Agonist.
PVNS Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the PVNS pipeline drugs market, download a free report sample
PVNS Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the PVNS pipeline drugs market are intravenous, oral, intratumor, and subcutaneous.
PVNS Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the PVNS pipeline drugs market, download a free report sample
PVNS Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the PVNS pipeline drugs market are Monoclonal Antibodies, Small Molecules, and Oligonucleotides.
PVNS Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the PVNS pipeline drugs market, download a free report sample
PVNS Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the PVNS pipeline drugs market are Bristol-Myers Squibb Co, Merck KGaA, Nippon Chemiphar Co Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, and SynOx Therapeutics Ltd.
PVNS Pipeline Drugs Market Analysis, by Companies
To know more about the PVNS pipeline drugs market companies, download a free report sample
PVNS Pipeline Drugs Market Report Overview
Key Targets | Macrophage Colony Stimulating Factor 1 Receptor, Bcr-Abl Tyrosine Kinase, Peroxisome Proliferator Activated Receptor Gamma, Programmed Cell Death 1 Ligand 1, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, and Toll Like Receptor 9 |
Key Mechanisms of Action | Macrophage Colony Stimulating Factor 1 Receptor Antagonist, Bcr-Abl Tyrosine Kinase Inhibitor, Peroxisome Proliferator Activated Receptor Gamma Agonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, and Toll Like Receptor 9 Agonist |
Key Routes of Administration | Intravenous, Oral, Intratumor, and Subcutaneous |
Key Molecule Types | Monoclonal Antibodies, Small Molecules, and Oligonucleotide |
Key Companies | Bristol-Myers Squibb Co, Merck KGaA, Nippon Chemiphar Co Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, and SynOx Therapeutics Ltd. |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of PVNS.
- The pipeline guide reviews pipeline therapeutics for PVNS by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in PVNS therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates PVNS therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for PVNS
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for PVNS.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the PVNS pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Merck KGaA
Nippon Chemiphar Co Ltd
Novartis AG
Regeneron Pharmaceuticals Inc
SynOx Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the PVNS pipeline drugs market?
Some of the targets of the PVNS pipeline drugs market are Macrophage Colony Stimulating Factor 1 Receptor, Bcr-Abl Tyrosine Kinase, Peroxisome Proliferator Activated Receptor Gamma, Programmed Cell Death 1 Ligand 1, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, and Toll Like Receptor 9.
-
What are the key mechanisms of action in the PVNS pipeline drugs market?
Some of the mechanisms of action of the PVNS pipeline drugs market are Macrophage Colony Stimulating Factor 1 Receptor Antagonist, Bcr-Abl Tyrosine Kinase Inhibitor, Peroxisome Proliferator Activated Receptor Gamma Agonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, and Toll Like Receptor 9 Agonist.
-
What are the key routes of administration in the PVNS pipeline drugs market?
The key routes of administration in the PVNS pipeline drugs market are intravenous, oral, intratumor, and subcutaneous.
-
What are the key molecule types in the PVNS pipeline drugs market?
The molecule types in the PVNS pipeline drugs market are Monoclonal Antibodies, Small Molecules, and Oligonucleotides.
-
Which are the leading companies in the PVNS pipeline drugs market?
Some of the leading companies in the PVNS pipeline drugs market are Bristol-Myers Squibb Co, Merck KGaA, Nippon Chemiphar Co Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, and SynOx Therapeutics Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.